Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18358 clinical trials
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

metastatic cancer
FGFR2
cancer
primary cancer
  • 154 views
  • 14 Dec, 2020
  • 155 locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828

FGFR1
myeloid neoplasm
lymphoid malignancy
  • 79 views
  • 14 Dec, 2020
  • 35 locations
featured
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been

solid tumor
solid tumors
  • 45 views
  • 14 Dec, 2020
  • 53 locations
featured
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

urinary tract cancer
  • 1062 views
  • 08 Dec, 2020
  • 62 locations
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder carcinoma
bladder cancer
urothelial carcinoma
metastatic urothelial carcinoma
  • 22 views
  • 14 Dec, 2020
  • 64 locations
featured
Prostate Cancer

People with prostate cancer are asked to participate in a research study being conducted by Montefiore Medical Center.  

  • 27 views
  • 18 Jan, 2019
  • 1 location
featured
Solid Tumors

People with solid tumors are asked to participate in a research study being conducted by Montefiore Medical Center.  

  • 11 views
  • 23 Nov, 2020
  • 1 location
featured
Hematological Malignancies

People with hematological malignancies are asked to participate in a research study being conducted by Albert Einstein College of Medicine.

  • 9 views
  • 09 Jan, 2020
  • 1 location
featured
Breast Cancer MonarchE

People with Breast Cancer are asked to participate in a research study being conducted by White Plains Hospital.

  • 288 views
  • 07 Nov, 2020
  • 1 location
featured
ER+/HER2- Breast Cancer

People with breast cancer are asked to participate in a research study being conducted by Montefiore Medical Center.  

  • 9 views
  • 27 Jan, 2020
  • 1 location